Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Entire DC Network
Cost-Efficient And Easy To Perform Pcr-Based Assay To Identify Met Exon 14 Skipping In Formalin-Fixed Paraffin-Embedded (Ffpe) Non-Small Cell Lung Cancer (Nsclc) Samples, Odharnaith O'Brien, Mark C. Wright, Cathal O'Brien, Orla Geoghegan, Niamh Leonard, Siobhan Nicolson, Sinead Cuffe, Aurelie Fabre, Wolfram Jochum, Markus Joerger, Steven G. Gray, Stephen P. Finn
Cost-Efficient And Easy To Perform Pcr-Based Assay To Identify Met Exon 14 Skipping In Formalin-Fixed Paraffin-Embedded (Ffpe) Non-Small Cell Lung Cancer (Nsclc) Samples, Odharnaith O'Brien, Mark C. Wright, Cathal O'Brien, Orla Geoghegan, Niamh Leonard, Siobhan Nicolson, Sinead Cuffe, Aurelie Fabre, Wolfram Jochum, Markus Joerger, Steven G. Gray, Stephen P. Finn
Articles
MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic …